Hims & Hers Health, Inc. (HIMS)
| Market Cap | 5.87B -6.6% |
| Revenue (ttm) | 2.37B +32.8% |
| Net Income | -13.24M |
| EPS | -0.06 |
| Shares Out | 231.46M |
| PE Ratio | n/a |
| Forward PE | 72.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,669,124 |
| Open | 25.21 |
| Previous Close | 29.14 |
| Day's Range | 24.56 - 26.84 |
| 52-Week Range | 13.74 - 70.43 |
| Beta | 2.42 |
| Analysts | Buy |
| Price Target | 30.33 (+19.6%) |
| Earnings Date | May 11, 2026 |
About HIMS
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and de... [Read more]
Financial Performance
In 2025, Hims & Hers Health's revenue was $2.35 billion, an increase of 59.00% compared to the previous year's $1.48 billion. Earnings were $128.37 million, an increase of 1.85%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for HIMS stock is "Buy." The 12-month stock price target is $30.33, which is an increase of 19.60% from the latest price.
News
Hims & Hers Drops After Earnings Miss & HIMS Options Trade
Marley Kayden breaks down Him & Hers (HIMS) after the company missed on both earnings and revenue. She explains how the end of the weight-loss drug shortage hurt their momentum, despite a rise in subs...
Hims & Hers Health Stock (HIMS) Sinks on Dismal Q1 Earnings and Outlook; Here’s What Analysts Are Saying
Hims & Hers Health ($HIMS) stock was down about 11% on Tuesday, as of writing, after the telehealth company reported a larger-than-anticipated loss for Q1 2026 and issued weak earnings…
Tuesday's Morning Movers: HIMS, ASTS & ONON Down on Earnings
Diane King Hall talks about notable earnings movers as markets open lower. Hims & Hers (HIMS) fell after a surprise loss as U.S. sales decline.
U.S.-Iran Ceasefire on "Life Support," HIMS & ASTS Earnings Sell-Off
The U.S.-Iran ceasefire is on "life support," according to President Trump, causing stocks to slide and crude oil to climb in the overnight hours. Kevin Green explains how the geopolitical headlines c...
5 Things to Know Before the Stock Market Opens
Stock futures are lower ahead of the release of a key inflation report, while oil prices rise amid a lack of progress in talks to end the Iran war; the Consumer Price Index for April is expected to sh...
Hims & Hers tumbles 15% after earnings miss as GLP-1 transition weighs on results
Shares of Hims & Hers Health (HIMS) fell sharply in premarket trading on Tuesday after the telehealth company reported weaker-than-expected first-quarter revenue and a surprise loss. The stock dropped...
Hims & Hers plummets 16% after first-quarter loss, weak earnings guidance
Digital health firm Hims & Hers' stock plummeted in premarket trading on weak first-quarter earnings. Hims reported a net loss of $92 million in the first quarter, up from $50 million last year.
Hims & Hers plunges after weight-loss pivot hits quarterly results
Shares of Hims & Hers Health fell 15% premarket on Tuesday after the telehealth company missed Wall Street estimates for first-quarter revenue and posted a surprise loss, hurt by changes in its weig...
Bullish flow in Hims and Hers Health with shares up 3.13%
Bullish flow in Hims and Hers Health (HIMS), with shares up 88c, or 3.13%, near $29.16. Options volume running well above average with 415k contracts traded and calls leading puts…
Notable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Hims & Hers (HIMS), consensus 3c… GoPro (GPRO), consensus (4c)… Rigetti Computing (RGTI), consensus (4c)… ZoomInfo ...
Hims & Hers Health reports Q1 EPS (40c) vs 20c last year
Reports Q1 revenue $608.1M, consensus $616.85M. “2026 is a defining year for Hims & Hers. We’re not just growing, we’re pulling away from the field on our path to becoming…
Hims & Hers Health sees Q2 revenue $680M-$700M, consensus $642.94M
Sees Q2 adjusted EBITDA $35M-$55M.
Hims & Hers Health raises FY26 revenue view to $2.8B-$3B from $2.7B-$2.9B
Consensus $2.72B. Cuts FY26 adjusted EBITDA view to $275M-$350M from $300M-$375M.
Hims & Hers Health Swings to First-Quarter Loss as Expenses Rise
The telehealth platform posted a quarterly loss of $92.1 million, offsetting a 4% increase in revenue.
Hims & Hers Health Earnings Call Transcript: Q1 2026
Q1 2026 saw 4% revenue growth to $608M and a strategic pivot to branded weight loss products, driving record subscriber additions and international expansion. Despite a GAAP net loss from restructuring, guidance was raised for 2026, with strong investments in technology and global scale.
Hims & Hers Stock Sinks. Why Earnings Offered Wall Street A Big Surprise.
Hims & Hers shares are falling after reporting disappointing first-quarter earnings results.
Hims & Hers raises 2026 revenue forecast on strong demand for personalized care
Hims & Hers Health raised its 2026 revenue forecast on Monday, betting on increased sales for its personalized healthcare offerings.
Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the first quarter...
Polymarket Earnings: Will HIMS, CRCL, QUBT Beat Earnings on Monday?
On Monday, May 11, Hims & Hers Health ($HIMS), Circle ($CRCL), and Quantum Computing ($QUBT) will report their earnings. Circle will report before the market open, while Hims & Hers and…
HIMS Stock Options Traders Are Pricing In a Huge Price Swing after Earnings
Hims & Hers Health ($HIMS) stock options traders are pricing in a sharp move ahead of the healthcare company’s earnings. With the stock trading around $26.25, we will use the…
Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the ...
Hims & Hers expands into menopause care as estrogen patch demand rises
Telehealth company Hims & Hers said on Wednesday it will now offer treatment options for perimenopause and menopause via its platform, as rising U.S. demand for hormone therapy strains supplies of e...
RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Investors are starting to focus on what will replace compounded GLP-1 driven growth for telehealth companies like Hims & Hers Health. Peptides are gaining attention as a potential new growth vector, d...
Hims rises as FDA considers broader peptides access; analysts see long-term win
Shares of Hims & Hers Health rose more than 7% on Thursday as analysts said the U.S. drug regulator's consideration to allow compounding pharmacies to manufacture popular peptides could benefit the t...